title: Cardiac troponin-I and risk of heart failure: a community-based cohort study.
abstract: OBJECTIVE
  We examined if circulating levels of cardiac troponin-I (cTnI) predict subsequent heart failure in the community.
  
  
  RESULTS
  Using Cox proportional hazards models, we examined the risk of a first hospitalization for heart failure during a maximum of 11.4 years in a community-based sample of 1089 70-year-old men without heart failure, valvular disease, or electrocardiographic left ventricular hypertrophy. Adjusting for smoking, systolic blood pressure, antihypertensive medication use, diabetes, body mass index, serum cholesterol, and myocardial infarction before baseline or during follow-up, 0.01 microg/L higher cTnI conferred a hazard ratio (HR) of 1.26 (95% confidence interval 1.15-1.38) for subsequent heart failure. Persons with cTnI > or =0.03 microg/L had an HR of 5.25 (2.00-13.77) compared with persons with cTnI <0.01 microg/L. Adjusting additionally for serum NTproBNP attenuated the estimates somewhat [HR 1.22 (1.11-1.34) per 0.01 microg/L of cTnI]. Excluding persons with myocardial infarction before baseline and censoring at time of myocardial infarction during follow-up, 0.01 microg/L higher cTnI was associated with a multivariable-adjusted HR of 1.31 (1.16-1.47) for heart failure.
  
  
  CONCLUSIONS
  In a community-based sample, a direct measure of cardiomyocyte damage, cTnI, indicated a substantially increased risk of heart failure, accounting for other risk factors. Studies investigating the clinical utility of measuring cTnI in asymptomatic individuals are warranted.
authors.affiliation: Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. johan.sundstrom@medsci.uu.se
authors.forename: Johan
authors.initials: J
authors.lastname: Sundström
authors.forename: Erik
authors.initials: E
authors.lastname: Ingelsson
authors.forename: Lars
authors.initials: L
authors.lastname: Berglund
authors.forename: Björn
authors.initials: B
authors.lastname: Zethelius
authors.forename: Lars
authors.initials: L
authors.lastname: Lind
authors.forename: Per
authors.initials: P
authors.lastname: Venge
authors.forename: Johan
authors.initials: J
authors.lastname: Arnlöv
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002637:Chest Pain / Q000150:complications* / Q000503:physiopathology; D015331:Cohort Studies; D006333:Heart Failure / Q000209:etiology*; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D032383:Myocytes, Cardiac / Q000378:metabolism*; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012307:Risk Factors; D011795:Surveys and Questionnaires; D019210:Troponin I / Q000097:blood*
chemical_list: D015415:Biomarkers; D019210:Troponin I